Hyaluronic acid-based gels including lidocaine
DCFirst Claim
Patent Images
1. A dermal filler comprising:
- hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), andlidocaine;
wherein the lidocaine is freely released in vivo;
wherein the dermal filler is sterile; and
wherein the dermal filler is made by a process comprising;
crosslinking HA with BDDE to obtain a crosslinked HA composition;
adding lidocaine to the crosslinked HA composition; and
heat sterilizing the crosslinked HA composition with added lidocaine to obtain a sterile dermal filler.
1 Assignment
Litigations
1 Petition
Accused Products
Abstract
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
253 Citations
30 Claims
-
1. A dermal filler comprising:
-
hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), and lidocaine; wherein the lidocaine is freely released in vivo; wherein the dermal filler is sterile; and wherein the dermal filler is made by a process comprising; crosslinking HA with BDDE to obtain a crosslinked HA composition; adding lidocaine to the crosslinked HA composition; and heat sterilizing the crosslinked HA composition with added lidocaine to obtain a sterile dermal filler. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. A dermal filler composition comprising:
-
a composition comprising hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), wherein the HA is not crosslinked to a non-HA biopolymer, and lidocaine; wherein the dermal filler is made by a process comprising; crosslinking HA with BDDE to obtain a crosslinked HA; adding lidocaine to the crosslinked HA; and heat sterilizing the crosslinked HA with added lidocaine to obtain a sterile dermal filler. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23)
-
-
24. A dermal filler composition comprising:
-
a hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), and about 0.3% lidocaine by weight, wherein the lidocaine is freely released in vivo and wherein the composition is sterile; wherein the composition is made by a process comprising; crosslinking HA with BDDE to obtain a crosslinked HA; adding a free HA gel to the crosslinked HA; adding a solution of lidocaine HCl to the crosslinked HA; and autoclaving the crosslinked HA having free HA gel and lidocaine HCl added thereto, to obtain a sterile dermal filler composition.
-
-
25. A dermal filler product comprising:
-
a dermal filler composition comprising a hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), and between about 0.1% to about 5.0% lidocaine by weight, wherein the HA is not crosslinked to a non-HA biopolymer, and wherein the composition is sterile; a syringe containing the sterile composition; wherein the product is made by a process comprising; crosslinking HA with BDDE to obtain a crosslinked HA; adding lidocaine to the crosslinked HA to obtain a crosslinked HA containing lidocaine; and packaging the crosslinked HA containing lidocaine in a syringe; and autoclaving the syringe containing the crosslinked HA containing lidocaine to obtain a dermal filler product. - View Dependent Claims (26, 27, 28, 29, 30)
-
Specification